Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Urology

PUBLISHER: Grand View Research | PRODUCT CODE: 1869869

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1869869

Hematuria Treatment Market Size, Share & Trends Analysis Report By Treatment Type (Pharmacotherapy, Procedural / Interventional Therapies, Adjunctive / Supportive Therapies), By Type, By Region, And Segment Forecasts, 2025 - 2033

PUBLISHED:
PAGES: 100 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 5950
Printable PDF & Excel (5-User License)
USD 6950
Printable PDF & Excel (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Hematuria Treatment Market Summary

The global hematuria treatment market size was estimated at USD 1,087.3 million in 2024 and is projected to reach USD 1,426.9 million by 2033, growing at a CAGR of 3.1% from 2025 to 2033. The market is driven by urological care and sustained by the growing prevalence of recurrent urinary tract infections, bladder cancer, and urolithiasis, alongside an expanding geriatric population.

Hematuria is the most common and vital early clinical sign for bladder cancer, which is a high-burden disease that requires extensive diagnostic and therapeutic resources. Moreover, the increasing incidence of bladder cancer cases globally is expected to drive the overall market growth. In the U.S., the American Cancer Society projects 84,870 new cases in 2025, reflecting stable incidence and continued reliance on diagnostic cystoscopy. Given that most bladder cancers require ongoing surveillance through repeated cystoscopy and risk-adapted intravesical therapy, rising case volumes drive the hematuria treatment industry.

Furthermore, rising urinary tract infection (UTI) incidence increases episodic hematuria presentations and empirical antibiotic use, which drives urgent evaluation demand and creates pressure for faster, point-of-care diagnostics. New rapid diagnostics have shortened pathogen identification, directly affecting hematuria treatment pathways by shortening time-to-diagnosis.

Urolithiasis prevalence and symptomatic stone events are important non-neoplastic causes of visible hematuria and often require definitive endourologic care (URS, PCNL) or imaging triage. Although some age-standardised rates have declined, absolute case counts, and new presentations have risen in many regions. It is characterized by symptoms and a high likelihood of recurrence and has created a considerable burden on the healthcare system, especially affecting individuals aged 20 to 54. This indicates substantial age-standardized incidence of stone disease and rising rates in many regions, which raises emergency and elective procedure volumes. Diagnostic cystoscopy remains among the most frequently performed urology procedures, so rising stone and hematuria referrals drive the industry.

Global Hematuria Treatment Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global hematuria treatment market report based on treatment type, type, and region:

  • Treatment Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharmacotherapy
  • Procedural / Interventional Therapies
  • Adjunctive / Supportive Therapies
  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Branded
  • Generic
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
Show more
Product Code: GVR-4-68040-783-3

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment type
    • 1.2.2. Type
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Treatment type outlook
    • 2.2.2. Type outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Hematuria Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Hematuria Treatment Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Hematuria Treatment Market: Treatment Type Estimates & Trend Analysis

  • 4.1. Treatment Type Segment Dashboard
  • 4.2. Hematuria Treatment Market: Treatment Type Movement Analysis
  • 4.3. Global Hematuria Treatment Market Size & Trend Analysis, by Treatment Type, 2021 to 2033 (USD Million)
    • 4.3.1. Pharmacotherapy
      • 4.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.3.2. Procedural / Interventional Therapies
      • 4.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.3.3. Adjunctive / Supportive Therapies
      • 4.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Hematuria Treatment Market: Type Estimates & Trend Analysis

  • 5.1. Type Segment Dashboard
  • 5.2. Hematuria Treatment Market: Type Movement Analysis
  • 5.3. Global Hematuria Treatment Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
    • 5.3.1. Branded
      • 5.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.3.2. Generic
      • 5.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Hematuria Treatment Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Dashboard
  • 6.2. Regional Market Share Analysis, 2024 & 2030
  • 6.3. Hematuria Treatment Market by Region: Key Takeaways
  • 6.4. North America
    • 6.4.1. U.S.
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework/reimbursement structure
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.2. Canada
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework/reimbursement structure
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5. Europe
    • 6.5.1. Germany
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.5.3. France
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.5.4. Italy
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/reimbursement structure
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.5.5. Spain
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework/reimbursement structure
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.5.6. Denmark
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework/reimbursement structure
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.5.7. Sweden
      • 6.5.7.1. Key country dynamics
      • 6.5.7.2. Regulatory framework/reimbursement structure
      • 6.5.7.3. Competitive scenario
      • 6.5.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.5.8. Norway
      • 6.5.8.1. Key country dynamics
      • 6.5.8.2. Regulatory framework/reimbursement structure
      • 6.5.8.3. Competitive scenario
      • 6.5.8.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Japan
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.6.2. China
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.6.3. India
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/reimbursement structure
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.6.4. South Korea
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework/reimbursement structure
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework/reimbursement structure
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.6.6. Thailand
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework/reimbursement structure
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Brazil
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.7.2. Mexico
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.8. MEA
    • 6.8.1. South Africa
      • 6.8.1.1. Key country dynamics
      • 6.8.1.2. Regulatory framework/reimbursement structure
      • 6.8.1.3. Competitive scenario
      • 6.8.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.8.2. Saudi Arabia
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework/reimbursement structure
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.8.3. UAE
      • 6.8.3.1. Key country dynamics
      • 6.8.3.2. Regulatory framework/reimbursement structure
      • 6.8.3.3. Competitive scenario
      • 6.8.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.8.4. Kuwait
      • 6.8.4.1. Key country dynamics
      • 6.8.4.2. Regulatory framework/reimbursement structure
      • 6.8.4.3. Competitive scenario
      • 6.8.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. Key company heat map analysis, 2024
  • 7.4. Company Profiles
    • 7.4.1. AstraZeneca
      • 7.4.1.1. Company overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Product benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. Bristol-Myers Squibb Company
      • 7.4.2.1. Company overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Product benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. F. Hoffmann-La Roche Ltd.
      • 7.4.3.1. Company overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Product benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. Johnson & Johnson and its affiliates
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. Merck & Co., Inc.
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. Novartis AG
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. Pfizer Inc.
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. Sun Pharmaceutical Industries Ltd.
      • 7.4.8.1. Company overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product benchmarking
      • 7.4.8.4. Strategic initiativesa
Show more
Product Code: GVR-4-68040-783-3

List of Tables

  • Table 1 List of abbreviations
  • Table 2 Global hematuria treatment market, by region, 2021 - 2033 (USD Million)
  • Table 3 Global hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 4 Global hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 5 North America hematuria treatment market, by country, 2021 - 2033 (USD Million)
  • Table 6 North America hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 7 North America hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 8 U.S. hematuria treatment, by treatment type, 2021 - 2033 (USD Million)
  • Table 9 U.S. hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 10 Canada hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 11 Canada hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 12 Europe hematuria treatment market, by country, 2021 - 2033 (USD Million)
  • Table 13 Europe hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 14 Europe hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 15 Germany hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 16 Germany hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 17 UK hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 18 UK hematuria treatment market, by drug, 2021 - 2033 (USD Million)
  • Table 19 France hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 20 France hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 21 Italy hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 22 Italy hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 23 Spain hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 24 Spain hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 25 Denmark hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 26 Denmark hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 27 Sweden hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 28 Sweden hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 29 Norway hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 30 Norway hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 31 Asia Pacific hematuria treatment market, by country, 2021 - 2033 (USD Million)
  • Table 32 Asia Pacific hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 33 Asia Pacific hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 34 Japan hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 35 Japan hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 36 China hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 37 China hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 38 India hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 39 India hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 40 South Korea hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 41 South Korea hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 42 Australia hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 43 Australia hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 44 Thailand hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 45 Thailand hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 46 Latin America hematuria treatment market, by country, 2021 - 2033 (USD Million)
  • Table 47 Latin America hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 48 Latin America hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 49 Brazil hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 50 Brazil hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 51 Mexico hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 52 Mexico hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 53 Argentina hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 54 Argentina hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 55 MEA hematuria treatment market, by country, 2021 - 2033 (USD Million)
  • Table 56 MEA hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 57 MEA hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 58 South Africa hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 59 South Africa hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 60 Saudi Arabia hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 61 Saudi Arabia hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 62 UAE hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 63 UAE hematuria treatment market, by type, 2021 - 2033 (USD Million)
  • Table 64 Kuwait hematuria treatment market, by treatment type, 2021 - 2033 (USD Million)
  • Table 65 Kuwait hematuria treatment market, by type, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews
  • Fig. 5 Market research approaches
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Hematuria treatment market: market outlook
  • Fig. 9 Hematuria treatment competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Hematuria treatment market driver impact
  • Fig. 14 Hematuria treatment market restraint impact
  • Fig. 15 Hematuria treatment market strategic initiatives analysis
  • Fig. 16 Hematuria treatment market: treatment type movement analysis
  • Fig. 17 Hematuria treatment market: treatment type outlook and key takeaways
  • Fig. 18 Pharmacotherapy market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 19 Procedural /Interventional therapies market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 20 Adjunctive / Supportive therapies market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 21 Hematuria treatment market: type movement analysis
  • Fig. 22 Hematuria treatment market: type outlook and key takeaways
  • Fig. 23 Branded market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Generic market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Global hematuria treatment market: Regional movement analysis
  • Fig. 26 Global hematuria treatment market: Regional outlook and key takeaways
  • Fig. 27 North America market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 U.S. market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 Canada market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 Europe market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 31 Germany market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 UK market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 France market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Italy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Spain market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Denmark market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Sweden market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Norway market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 Asia Pacific market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Japan market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 41 China market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 India market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 South Korea market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Australia market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 Thailand market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Latin America market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 Brazil market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 Mexico market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 Argentina market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 Middle East and Africa market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 South Africa market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Saudi Arabia market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 UAE market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 54 Kuwait market estimates and forecasts, 2021 - 2033 (USD Million)
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!